GlassScriptPhysician profile
Rudra Beharrysingh
NPI 1366726077
$842.58
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $97.12 · 2021: $188 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $258.93 | 2019-2021 | |
| Allergan, INC. | $182.44 | 2019-2020 | |
| Boston Scientific Corporation | $118.55 | 2022 | |
| Novo Nordisk INC | $66.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $64.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.94 | 2020-2021 | |
| Vifor Pharma, INC. | $24.01 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.54 | 2019 | |
| Amarin Pharma, INC. | $14.79 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudra Beharrysingh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.